Cellipont Bioservices, a cell therapy Contract Development and Manufacturing Organization (CDMO), and Xiogenix, an innovator in biopharmaceutical technology, have joined forces, enabling Cellipont Bioservices to offer its clients access to the Ares X20 fill and finish system, significantly enhancing the precision and efficiency of its cell therapy product filling processes.
 
The Xiogenix Ares X20 is a fill-and-finish system designed to revolutionize cell and gene therapy production. It offers precise temperature control, automated formulation, and high-throughput capabilities, efficiently processing multiple containers in under five minutes. By minimizing residual air and waste, it ensures high-quality and consistent formulations. The Ares X20’s scalability and automation enhance the precision, safety, and efficiency of therapy production, representing a significant advancement in the field and potentially accelerating the time to market for new treatments. By integrating this technology, Cellipont Bioservices aims to optimize the manufacturing process further, ensuring high standards of quality and safety.
 
“This partnership with Xiogenix marks another significant milestone for Cellipont Bioservices,” said Darren Head, CEO of Cellipont Bioservices. “We are committed to adopting advanced technologies that drive innovation and excellence in biopharmaceutical manufacturing. Through this collaboration with Xiogenix, we offer our clients access to an advanced fill-and-finish system, enhancing our service offerings and delivering superior solutions.”
 
“We are thrilled to partner with Cellipont Bioservices to bring ourAres X20 fill and finish system to a broader range of clients,” said Rachel Bahr, CEO of Xiogenix. “This collaboration aligns with our mission to provide innovative solutions that enhance the efficiency and reliability of biopharmaceutical manufacturing. We look forward to seeing the positive impact this partnership will have on the industry.”